Nanoparticle Vaccine to combat Necrotic enteritis in poultry

The Need: Addressing the Global Threat of Necrotic Enteritis in Poultry

Necrotic enteritis (NE) poses a significant commercial challenge to the poultry industry, with estimated annual costs reaching up to 5-6 billion USD worldwide. The disease, caused by Clostridium perfringens, affects broilers, laying hens, turkeys, and quail. Clinical infections result in severe symptoms and high mortality rates, while the chronic, subclinical form causes economic losses through reduced growth and feed conversion rates. With the increasing demand to remove antibiotic growth promoters from poultry feed, the prevalence and severity of necrotic enteritis infections are on the rise. To combat this growing concern, a safe and effective vaccine is required to protect poultry and maintain industry productivity.

The Technology: Introducing the Pioneering Nanoparticle-Based Vaccine

The revolutionary technology comprises a nanoparticle-based vaccine designed to combat necrotic enteritis in poultry effectively. The vaccine is formulated with one or more Clostridium perfringens extracellular proteins, derived from a culture supernatant, and incorporated within polyanhydride or chitosan nanoparticles. These nanoparticles serve as potent carriers for delivering the protective antigens and promoting a robust immune response against the pathogen. Additionally, the vaccine may include a Salmonella enteritidis flagellar protein as well as an adjuvant, enhancing its efficacy.

Commercial Applications: Versatile Applications for Enhanced Poultry Health

The nanoparticle-based vaccine offers numerous commercial applications, providing an efficient solution for combating necrotic enteritis in poultry and ensuring better productivity and profitability for poultry producers. Some key applications include:

  • Prevention of Necrotic Enteritis: The vaccine is designed to offer robust protection against Clostridium perfringens, reducing the incidence and severity of necrotic enteritis in poultry flocks.

  • Broiler and Layer Health: Administering the vaccine to broilers and laying hens aids in controlling both clinical and subclinical forms of the disease, maintaining the health and well-being of these birds.

  • Turkey and Quail Protection: The technology is equally applicable to turkeys and quails, safeguarding these poultry species from the detrimental effects of necrotic enteritis.

Benefits/Advantages: Advancing Poultry Industry and Health

The nanoparticle-based vaccine presents several distinct benefits and advantages over traditional prevention methods, making it an indispensable technology for the poultry industry:

  • Antibiotic-Free Solution: As a non-antibiotic alternative, the vaccine aligns with the growing industry trend to eliminate antibiotic growth promoters from feed, while still maintaining optimal flock health.

  • Enhanced Immune Response: The innovative nanoparticle delivery system ensures efficient uptake and presentation of antigens, resulting in a robust humoral and cellular immune response.

  • Versatile Oral Delivery: The vaccine can be conveniently administered through oral delivery, reducing stress on birds and simplifying the vaccination process.

  • Multi-Species Protection: With its efficacy against various Clostridium perfringens types, the vaccine provides protection across multiple poultry species, accommodating diverse farm operations.

  • Increased Productivity: By significantly reducing the economic impact of necrotic enteritis, the vaccine enhances overall productivity and profitability for poultry producers.

The nanoparticle-based vaccine represents a game-changing advancement in poultry health, addressing the critical need for an effective, antibiotic-free solution to combat necrotic enteritis. Embrace this innovative technology today to secure your poultry operations against this pervasive threat and drive sustainable growth in the poultry industry.


Patent # Title Country

Loading icon